NOTIFICATION AND FORM FOR ADVANCE VOTING

by postal voting in accordance with section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of shareholders' meetings in companies and other associations.

To be received by Ascelia Pharma AB no later than Tuesday 4 May 2021.

The shareholder set out below hereby notifies the company of its participation and exercises its voting right for all of the shareholder's shares in Ascelia Pharma AB, Reg. No. 556571-8797, at the annual general meeting on Wednesday 5 May 2021. The voting right is exercised in accordance with the voting options marked in <u>Schedule 1</u> below.

Name of the shareholder:	Personal identification number or corporate registration number:

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date:	
Signature:	
Clarification of signature:	
Telephone number:	E-mail:

If issued by a legal entity, the form must be signed by authorized representative(s) and be accompanied by a registration certificate or, concerning foreign legal entities, corresponding documents evidencing the authorized representative(s) of the shareholder. The same applies if the shareholder votes in advance through a proxy.

The form, and a copy of the registration certificate or corresponding documents (if applicable) shall be sent to Ascelia Pharma AB, att: Kristian Borbos, Hyllie Boulevard 34, SE-215 32 Malmö, Sweden, or via e-mail to: kb@ascelia.com. The completed form must be submitted to Ascelia Pharma AB no later than on Tuesday 4 May 2021.

In Schedule 1, the votes shall be set forth. A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. Only one form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The latest form received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. For complete proposals for resolutions, please refer to the notice of the annual general meeting and the complete proposals, available on the company's website (www.ascelia.com).

Should you have any questions, please contact Ascelia Pharma AB via e-mail address kb@ascelia.com or phone number +46 735 17 91 13. For information on how your personal data is processed, see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Please note that submitting this form will be regarded as giving notice of your attendance at the meeting. Please note that a prerequisite for an advance vote to be taken into account is that the shareholder who has cast the vote is registered in his/her own name in the share register kept by Euroclear Sweden AB prior to the meeting. Further instructions on this can be found in the notice to the annual general meeting.

This form for advance voting may be revoked by written notice to Ascelia Pharma AB on the address above or via e-mail to kb@ascelia.com, no later than Tuesday 4 May 2021.

Schedule 1 – Voting form for advance voting at annual general meeting in Ascelia Pharma AB on 5 May 2021

The voting alternatives below refer, unless otherwise stated in the form, to the proposals stated in the notice to the annual general meeting.

1. Election of chairman of the meeting		Yes □	No □
2. Preparation and approval of the voting list		Yes □	No □
3. Approval of the agenda		Yes □	No □
4. Elect	ion of one or two persons who shall approve the minutes of the meeting	Yes □	No □
5. Deter	rmination of whether the meeting was duly convened	Yes □	No □
7. Reso	lutions regarding		
	adoption of the income statement and the balance sheet and the consolidated income statement and the consolidated balance sheet	Yes □	No □
	allocation of the company's profits in accordance with the adopted balance sheet	Yes □	No □
	discharge of the members of the board of directors and the CEO from iability		
á	a. Magnus Corfitzen (as CEO)	Yes □	No □
ŀ	b. Peter Benson	Yes □	No □
C	c. Niels Mengel	Yes □	No □
C	d. Bo Jesper Hansen	Yes □	No □
•	e. René Spogárd	Yes □	No □
f	f. Helena Wennerström	Yes □	No □
Ç	g. Hans Maier	Yes □	No □
ŀ	h. Lauren Barnes	Yes □	No □
8. Deter	rmination of		
a. t	he number of members of the board of directors	Yes □	No □
b. t	he number of auditors and deputy auditors	Yes □	No □
9. Deter	rmination of		
a. r	emuneration for the members of the board of directors	Yes □	No □
b. r	emuneration for the auditors	Yes □	No □
	ction of members of the board of directors and chairman of the board of ctors		
a. I	Peter Benson (re-election)	Yes □	No □
b. 1	Niels Mengel (re-election)	Yes □	No □
c. I	Bo Jesper Hansen (re-election)	Yes □	No □
d. I	René Spogárd (re-election)	Yes □	No □
e. I	Helena Wennerström (re-election)	Yes □	No □
f. I	Hans Maier (re-election)	Yes □	No □
g. l	Lauren Barnes (re-election)	Yes □	No □
h. (Chairman of the board of directors: Peter Benson (re-election)	Yes □	No □
11. Elec	ction of auditors	Yes □	No □

12. Resolution on approval of remuneration report	Yes □	No □			
13. Resolution on authorization for the board of directors regarding issues	Yes □	No □			
14. Resolution on implementation of a long-term incentive program by way of (A) implementation of a performance-based share saving program; (B) authorization on directed issues of series C shares; (C) authorization for repurchase of series C shares; and (D) resolution on transfer of own ordinary shares	Yes □	No □			
The shareholder wishes that resolution(s) under one or several items in the form shall be deferred to a continued shareholders' meeting					
(completed only if the shareholder has such a wish)					
List item or items (use numbers):					